Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (MS). Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration and is preparing for a Phase 2 clinical trial following successful completion of Phase 1 safety studies and key toxicology programs.
More than a decade of preclinical research supports Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated and chronic inflammatory disease treatment markets.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company also retains ownership in Unbuzzd Wellness Inc. and receives royalty payments from sales of Unbuzzd products.
For more information, see the full press release at https://ibn.fm/6ylQf.
